Publications / Policy Memo

The Value of the Medicare Part D Program for its Beneficiaries and the Medicare System

By / 12.7.2016

In the United States and other advanced countries, governments and individuals regularly lament the high and ever-rising costs of healthcare; and the ongoing aging of their populations virtually ensures that these costs will continue to increase — perhaps at substantial rates.

Many analysts identify the development and broad use of new healthcare technologies as primary sources of these cost increases; and, in the public debate over rising costs, new prescription drugs are often singled out as critical cost drivers. This study examines the cost-benefit calculus for prescription drugs in the context of Medicare and overall healthcare in the United States.

 


Download (PDF, Unknown)